Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
Rhea-AI Summary
Iridex (Nasdaq: IRIX) announced a newly published computational study in Translational Vision Science & Technology modeling thermal dynamics of transscleral glaucoma lasers.
The Monte Carlo simulations compared continuous-wave TSCPC (CW-TSCPC) and MicroPulse TLT using Iridex Cyclo G6, G-Probe and MicroPulse P3. Results: CW-TSCPC produced a ~2 mm thermal zone with temperatures >100°C for ~2.2 seconds, while MicroPulse TLT produced a smaller 0.6–1.2 mm zone with peak temperatures below 100°C and more uniform heat distribution.
Authors say both techniques lie on a thermal continuum and may serve complementary clinical roles with further optimization.
Positive
- MicroPulse TLT thermal zone of 0.6–1.2 mm
- MicroPulse TLT peak temperatures remained below 100°C
- MicroPulse TLT showed more uniform heat distribution
- Study used advanced Monte Carlo simulations for quantitative comparison
Negative
- CW-TSCPC produced a 2 mm heating zone exceeding 100°C for ~2.2 seconds
Key Figures
Market Reality Check
Peers on Argus
IRIX is up 1.33% while key peers like TRIB (-2.57%), ADGM (-10.1%), PTHL (-7.85%), and VVOS (-4.17%) are down, pointing to a stock-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Q3 2025 earnings | Positive | +8.2% | Revenue growth, lower opex, and improved adjusted EBITDA outlook. |
| Oct 28 | Earnings schedule | Neutral | +2.0% | Announcement of Q3 2025 results release and conference call logistics. |
| Sep 09 | Nasdaq compliance | Positive | -2.8% | Regained compliance with Nasdaq stockholders’ equity listing rules. |
| Aug 12 | Q2 2025 earnings | Negative | -9.2% | Net loss and margin pressure despite revenue growth and cost cuts. |
| Jul 29 | Earnings schedule | Neutral | -0.7% | Scheduling of Q2 2025 results and related investor call details. |
Earnings updates have produced larger price swings, with positive Q3 numbers drawing an upside reaction, while prior mixed earnings and even clearly positive listing-compliance news saw weaker or negative moves.
Over the last six months, IRIDEX has focused on stabilizing operations and communicating financial progress. Q2 and Q3 2025 earnings showed year-over-year revenue growth and cost reductions, though profitability remained a challenge. The company also resolved a prior Nasdaq equity compliance issue, with stockholders’ equity rising to $4.681M. Insider and regulatory filings highlighted new preferred equity and a convertible note supporting liquidity. Against this backdrop, the new glaucoma thermal dynamics study further reinforces the clinical and technological foundation behind its glaucoma laser franchise.
Market Pulse Summary
This announcement highlights a TVST study using Monte Carlo modeling to compare thermal effects of CW-TSCPC and MicroPulse TLT on the ciliary body, showing smaller and cooler thermal zones for MicroPulse TLT. It reinforces the clinical rationale behind IRIDEX’s glaucoma platform rather than near-term financials. In context of recent Q3 2025 revenue of $12.5M and ongoing net losses, investors may watch for how such data translate into probe and system adoption and future earnings reports.
Key Terms
transscleral cyclophotocoagulation medical
AI-generated analysis. Not financial advice.
MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma.1
Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy using MicroPulse® technology (MicroPulse TLT) with Iridex’s Cyclo G6® Laser, G-Probe® and MicroPulse P3® delivery devices.
Using advanced Monte Carlo computer simulations, the authors modeled how each technique heats the ciliary body and quantified temperature peaks, duration, and thermal spread. The modeling revealed that CW TSCPC produced a 2 mm-wide zone of tissue heating with temperatures exceeding 100°C for approximately 2.2 seconds. MicroPulse TLT generated a smaller 0.6-1.2 mm thermal zone and shorter duration peak temperatures, remaining below 100°C. Additionally, MicroPulse TLT showed a more uniform heat distribution than CW-TSCPC.
Dr. Grippo explained, “Our study uses a computational model to analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments. By linking these findings to the safety, effectiveness, and mechanisms of action described in the literature for both treatments, we can reinterpret existing clinical evidence from a fresh perspective. This approach strengthens our understanding and conceptual framework for these techniques and provides insights that may help refine both laser procedures for improved patient outcomes.”
The authors concluded that both techniques share a thermal continuum, and with further optimization, each may evolve to serve distinct but complementary roles from refractory glaucoma to earlier intervention cases.
“Dr. Grippo’s work underscores Iridex’s commitment to advancing evidence-based innovation in glaucoma care,” said Patrick Mercer, CEO of Iridex Corporation. “By deepening our scientific understanding of how these two transscleral laser approaches interact with ocular tissues, we can continue to improve treatment optimization and safety creating broad clinical opportunities for both CW-TSCPC and MicroPulse TLT in modern glaucoma management.”
The article is available in Translational Vision Science & Technology.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
Media Contact
Joan Stauffer
jstauffer@iridex.com
For more information about Iridex technologies, visit www.iridex.com.
Iridex, the Iridex logo, MicroPulse®, the MicroPulse logo, Cyclo G6, MicroPulse P3®, and G-Probe® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.
References
- Grippo TM, LaMarche K, Davreux AM, Stauffer J, Stacey S, Arnold K. Thermal tissue modeling of the ciliary body with continuous wave transscleral cyclophotocoagulation and transscleral laser therapy using micropulse technology. Transl Vis Sci Technol. 2025;14(11):32.
FAQ
What did the Iridex (IRIX) study published Dec 8, 2025 compare?
How do thermal peaks differ between CW-TSCPC and MicroPulse TLT in the IRIX study?
What are the clinical implications of the IRIX thermal dynamics findings for glaucoma treatment?
Which Iridex devices were modeled in the Dec 8, 2025 study?
Where was the Iridex thermal dynamics study published and who led it?
